Europe Respiratory Inhalers Market

The Europe respiratory inhalers market is expected to grow from US$ 7,674.02 million in 2022 to US$ 10,470.53 million by 2028. It is estimated to register a CAGR of 5.3% from 2022 to 2028.         

Rising Cases of Respiratory Disorders Fueling Europe Respiratory Inhalers Market Growth

The prevalence of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory diseases is increasing across the region. In addition, one of the major causes of respiratory diseases such as COPD and asthma is the rise in air pollution. The Organization for Economic Co-operation and Development (OECD) estimates that global emissions of greenhouse gases are likely to increase by ~50% by 2050, mainly due to a 70% increase in CO2 emissions. In addition, it is estimated that the atmospheric concentration of greenhouse gases could reach 685 parts per million (ppm) CO2 equivalent by 2050, which would cause average temperatures to rise 3–6ºC above pre-industrial levels. In addition, the beneficial effects on patients through combination therapy for asthma have increased, which has increased the demand for respiratory inhalers such as dry powder inhalers and soft-mist inhalers, as they are one of the best ways to administer combination drugs. Hence, the increasing prevalence of respiratory diseases among the growing population is one of the factors driving the Europe respiratory inhalers market.

Europe Respiratory Inhalers Market Overview

Europe includes France, Germany, Italy, Spain, the UK, and the Rest of Europe. The region is expected to witness a steady growth rate of 5.3% from 2022 to 2028. Germany dominated the Europe respiratory inhalers market in 2022. According to the OECD 2021 report, there was an increase in the cases of respiratory diseases such as COPD and influenza (particularly during the COVID-19 pandemic) in Germany. As per the Federal Statistical Office (Destatis), Germany, ~75,500 people died of smoking-specific illnesses in Germany in 2020; 46,100 of these cases were due to lung, bronchial, laryngeal, or tracheal cancer, and 29,400 due to COPD. It also reported that the risk of women dying from such illnesses had risen significantly in the last 20 years. In 2020, 40 women per 100,000 inhabitants died of lung and bronchial cancer, corresponding to ~73% of lung and bronchial cancer. Further, according to Germany's Robert Koch Institute (RKI), 4.5 million people suffered from an acute respiratory illness (ARE) within one week at the end of June and the beginning of July in 2022. Thus, the increasing prevalence of respiratory diseases in the country is expected to fuel the demand for respiratory inhalers.

Europe Respiratory Inhalers Market Revenue and Forecast to 2028 (US$ Million)

Europe Respiratory Inhalers Strategic Insights

Strategic insights for the Europe Respiratory Inhalers provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Respiratory Inhalers Report Scope

Europe Respiratory Inhalers Regional Insights

The geographic scope of the Europe Respiratory Inhalers refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Respiratory Inhalers Market Segmentation

The Europe respiratory inhalers market is segmented based on product type, technology, disease indication, and country.

Based on product type, the Europe respiratory inhalers market is segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment held the largest share of the Europe respiratory inhalers market in 2022.

Based on technology, the Europe respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held a larger share of the Europe respiratory inhalers market in 2022.  

Based on disease indication, the Europe respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the Europe respiratory inhalers market in 2022.   

Based on country, the Europe respiratory inhalers market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe respiratory inhalers market in 2022.   

AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd; GSK Plc; Koninklijke Philips NV; OMRON Corp; OPKO Health, Inc; PARI Respiratory Equipment, Inc.; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Europe respiratory inhalers market.